Eli Lilly Boosts Orforglipron GLP-1 Pill Production with Major Investments in China and Inventory Buildup

on

Eli Lilly is ramping up production of its GLP-1 pill orforglipron, with pre-launch inventory capitalized at $1.5 billion as of its 2025 annual report to avoid past shortages2.

Eli Lilly plans to invest $3 billion in China and submitted a marketing application for orforglipron to China's drug regulator at the end of 20255.

Eli Lilly has built nearly $550 million worth of orforglipron-related inventory by February 2025 and is constructing four new US manufacturing facilities as part of a $27 billion investment for weight loss therapies2.

Orforglipron outperformed Novo Nordisk's oral semaglutide in trials for blood sugar, weight loss, and heart health, with potential US approval as early as Q2 202614.

No specific $500M pledge to South Korea is detailed in recent reports; focus remains on US stockpiling, China investment, and global production strategies125.

Sources:

1. https://www.businessinsider.com/eli-lillys-orforglipron-beats-novo-nordisk-glp1-pill-in-tests-2026-2

2. https://www.pharmaceutical-technology.com/news/eli-lilly-builds-orforglipron-cache-to-avoid-previous-glp-1ra-shortages/

4. https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/

5. https://uk.investing.com/news/stock-market-news/eli-lilly-to-invest-3-billion-in-china-seeks-approval-for-new-glp1-drug-93CH-4552351